Acerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
Acerus Pharmaceuticals Corporation today announced it will host a Key Opinion Leader (KOL) meeting on new, unique clinical evidence supporting the expanded use of NATESTO® for the treatment of hypogonadism on Wednesday, October 30th in New York City.
The event will feature a presentation by KOL Dr. Ranjith Ramasamy, MD, University of Miami, who will discuss the current treatment landscape, unmet medical need, and new clinical evidence for men with hypogonadism. Dr. Ramasamy will be available to answer questions at the conclusion of the presentation.
Acerus Pharma’s management team will provide an update on the global commercialization of NATESTO®, the company’s core asset. As well, management will discuss the company’s revised strategy for the U.S. market and their pending restated partnership with Aytu BioScience.
Ranjith Ramasamy is the Director of Reproductive Urology as well as an Associate Professor in Department of Urology at the University of Miami in Florida. Dr. Ramasamy completed his Urology residency training at Weil Cornell Medical College and New York-Presbyterian Hospital. He then completed a National Institutes of Health sponsored fellowship in Male Reproductive medicine and Surgery at Baylor College of Medicine. To date, he has published over 200 manuscripts in peer-reviewed journals and several book chapters; he currently serves on the editorial board of several journals. Outside of clinical medicine and academic research, Dr. Ramasamy has made a significant effort to share his wealth of knowledge and serve as a mentor for future urologists. He created ‘Urology’ an app used by trainees across the world to help prepare for urology board examinations. As a physician, Dr. Ramasamy maintains a dedication to patient care, academia and the training of future urologists by directing a fellowship program in Andrology. Dr. Ramasamy is currently leading important clinical trials at the University of Miami for erectile dysfunction, Peyronie's disease and hypogonadism.
